<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908191</url>
  </required_header>
  <id_info>
    <org_study_id>ABI-H0731-101</org_study_id>
    <nct_id>NCT02908191</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Volunteers and Patients With Chronic Hepatitis B</brief_title>
  <official_title>A Phase 1a/1b, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ABI-H0731 in Healthy Volunteers and Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assembly Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assembly Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This two-part, Phase 1 protocol will be the first clinical study of ABI-H0731. Part I will be
      a Phase 1a dose-ranging assessment of ABI-H0731 in healthy adult volunteers. If the
      dose-related safety, tolerability and pharmacokinetics (PK) of ABI-H0731 in human volunteers
      are deemed satisfactory, then the study will advance to Part II, a Phase 1b dose-ranging
      assessment of ABI-H0731 in non-cirrhotic, CHB patients.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">March 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of healthy volunteers and patients with chronic HBV infection with treatment-related adverse events as assessed by CTCAE v4.0.</measure>
    <time_frame>Up to 57 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>ABI-H0731 or Matching Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABI-H0731 in varying doses of tablets by mouth for 1 day, 7 days, or 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABI-H0731 or Placebo and ETV or TDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABI-H0731 and entecavir or tenofovir in combination in a yet to be determined dose by mouth for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABI-H0731 or Placebo and a Nucleos(t)ide and Pegasys</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABI-H0731 or Placebo, in combination with a commerically-approved nucleos(t)ide plus PegIFN in treatment-experienced patients, for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-H0731</intervention_name>
    <arm_group_label>ABI-H0731 or Matching Placebo</arm_group_label>
    <arm_group_label>ABI-H0731 or Placebo and ETV or TDF</arm_group_label>
    <arm_group_label>ABI-H0731 or Placebo and a Nucleos(t)ide and Pegasys</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for ABI-H0731</intervention_name>
    <arm_group_label>ABI-H0731 or Matching Placebo</arm_group_label>
    <arm_group_label>ABI-H0731 or Placebo and ETV or TDF</arm_group_label>
    <arm_group_label>ABI-H0731 or Placebo and a Nucleos(t)ide and Pegasys</arm_group_label>
    <other_name>Sugar pill manufactured to mimic the ABI-H0731 tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Used to treat adults with chronic hepatitis B virus</description>
    <arm_group_label>ABI-H0731 or Placebo and ETV or TDF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate</intervention_name>
    <description>Used to treat adults with chronic hepatitis B virus</description>
    <arm_group_label>ABI-H0731 or Placebo and ETV or TDF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegasys</intervention_name>
    <description>Used to treat adults with chronic hepatitis B virus who show signs of liver damage</description>
    <arm_group_label>ABI-H0731 or Placebo and a Nucleos(t)ide and Pegasys</arm_group_label>
    <other_name>peginterferon alfa-2a</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nucleos(t)ide</intervention_name>
    <description>Used to treat adults with chronic hepatitis B virus</description>
    <arm_group_label>ABI-H0731 or Placebo and a Nucleos(t)ide and Pegasys</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Healthy volunteers:

          1. Male or female between 18 and 65 years old with a BMI of 18-32kg/m2

          2. Must be in good health and not have any health condition which could interfere with
             the absorption, distribution or elimination of study drug, or with the clinical and
             laboratory assessments in this study

        CHB patients:

          1. Male or female between 18 and 65 years of age, with a BMI of 18-35kg/m2 and a minimum
             body weight of 45 kg

          2. Must have chronic hepatitis B with no history of clinical decompensation

          3. Seropositive for HIV, HCV, or HDV antibody at Screen

          4. Previous treatment with any HBV antiviral treatments within the last 3 months

          5. Other known cause of liver disease, including NASH
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2016</study_first_submitted>
  <study_first_submitted_qc>September 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

